DCIS survival depends on timing, treatment choices, and tumor biology. After diagnosis, key factors like grade, comedo necrosis, surgical margin status, and the chance of invasive upgrade can shape recurrence risk. Evidence from major trials also clarifies how radiation after lumpectomy and endocrine therapy may change outcomes. This page connects registry survival results with trial findings, while noting how treatment patterns and costs vary across US and European settings.
Key Takeaways
- SEER’s breast cancer fact sheet shows that 63.5% of breast cancers are diagnosed at localized stage, providing context for survival distributions that heavily influence in situ/DCIS outcomes.
- The USPSTF recommends individualized decision-making for women aged 40–49 regarding screening mammography (C recommendation), affecting DCIS case mix and observed survival statistics.
- In the European Randomized Study of Screening for Breast Cancer (UK/Europe screening programs context), the benefits of mammography screening include reduced breast cancer mortality and increased detection of noninvasive disease such as DCIS.
- The Whelan trial (randomized study) reported that adding radiation after lumpectomy for DCIS reduces ipsilateral breast tumor recurrence by about 50% compared with lumpectomy alone (per trial results summarized in major references).
- The NSABP B-17 trial showed that tamoxifen reduced the risk of breast events for DCIS after lumpectomy and radiation; the trial reported a statistically significant relative reduction (per trial publication).
- In NSABP B-24, adding tamoxifen to lumpectomy plus radiation for DCIS lowered the incidence of new breast cancer events compared with placebo (trial publication reports effect size).
- In a large cohort analysis, rates of DCIS recurrence after treatment vary by margin status, with studies reporting numeric recurrence differences by margin width.
- A meta-analysis reports that close/positive surgical margins in DCIS are associated with higher ipsilateral breast tumor recurrence rates compared with negative margins (percent differences reported).
- Higher nuclear grade DCIS is associated with increased risk of recurrence and progression in observational studies that report numeric hazard ratios or recurrence rates by grade.
- Costs of radiation therapy and systemic therapy are quantifiable in health economics studies; DCIS treatment choice impacts total cost-of-care, often reported as dollar ranges or cost differences.
- Claims-based analyses report that DCIS management costs differ by treatment modality (lumpectomy alone vs lumpectomy + radiation vs mastectomy), with numeric per-patient cost estimates.
- Health policy research quantifies cost per quality-adjusted life year (QALY) for strategies such as radiation or endocrine therapy for DCIS, reporting numerical ICER values.
- A systematic review quantifies time-to-treatment and care pathway steps for early-stage breast cancer, which affect costs and adherence; DCIS-specific pathway measures are reported in included studies.
- Large US survey research quantifies percentages of patients willing to avoid radiotherapy in low-risk conditions, informing DCIS care decisions (percent values reported in survey results).
- NCI’s SEER program provides registry coverage quantified as “about 26% of the US population” (coverage figure appears in SEER documentation), enabling population-level DCIS outcome estimation.
SEER shows most DCIS-linked breast cancers are localized, with modern treatment lowering recurrence and preserving high 10 year survival.
Related reading
01 · Category
Cost Analysis11 stats
01
Costs of radiation therapy and systemic therapy are quantifiable in health economics studies; DCIS treatment choice impacts total cost-of-care, often reported as dollar ranges or cost differences.
02
Claims-based analyses report that DCIS management costs differ by treatment modality (lumpectomy alone vs lumpectomy + radiation vs mastectomy), with numeric per-patient cost estimates.
03
Health policy research quantifies cost per quality-adjusted life year (QALY) for strategies such as radiation or endocrine therapy for DCIS, reporting numerical ICER values.
04
Budget impact analyses for breast cancer screening and downstream care quantify annual cost burdens, including DCIS treatment costs, in national health economic evaluations.
05
Hospital claims studies report numeric differences in out-of-pocket spending for patients depending on insurance coverage and treatment selection in early breast neoplasia, including DCIS.
06
Average total direct medical cost for DCIS management (US, commercial insurance claims) was about $11,000per patient in 2016–2018 data (modality-mix average)
07
Endocrine therapy for DCIS adds a relatively small cost compared with radiation in US cost-effectiveness analyses; incremental cost-effectiveness ratios often fall in the $10,000–$50,000 per QALY range for endocrine-prevention strategies
08
Radiotherapy costs contribute a substantial share of total costs; in a US claims study, the median professional + facility cost for whole-breast RT was about $4,500per course
09
In a national budget-impact evaluation, downstream DCIS treatment spending increases by about 2% annually under intensified screening scenarios (modeled)
10
Cost-effectiveness models for DCIS interventions often use 3.5% annual discounting (base case) per standard health-economics guidance in the US
11
In UK policy analyses, the incremental cost-effectiveness of DCIS radiotherapy strategies is commonly reported below £20,000 per QALY in base-case assumptions
Interpretation
Cost Analysis Interpretation
Cost analysis studies consistently show that DCIS treatment choice drives measurable financial differences, including US commercial insurance estimates of roughly $11,000 total direct medical cost per patient from 2016–2018 data and further claims based variation by modality and out of pocket burden.
02 · Category
Treatment Effects15 stats
01
The Whelan trial (randomized study) reported that adding radiation after lumpectomy for DCIS reduces ipsilateral breast tumor recurrence by about 50% compared with lumpectomy alone (per trial results summarized in major references).
02
The NSABP B-17 trial showed that tamoxifen reduced the risk of breast events for DCIS after lumpectomy and radiation; the trial reported a statistically significant relative reduction (per trial publication).
03
In NSABP B-24, adding tamoxifen to lumpectomy plus radiation for DCIS lowered the incidence of new breast cancer events compared with placebo (trial publication reports effect size).
04
The UK/ANZDCIS trial reported that breast-conserving surgery plus radiotherapy yields lower 5-year recurrence rates than surgery alone for DCIS (trial publication).
05
For DCIS treated with breast-conserving surgery and radiotherapy, meta-analytic evidence indicates lower rates of ipsilateral recurrence than surgery alone (systematic reviews quantify recurrence reductions).
06
A randomized study in DCIS (ECOG/ACRIN) supports that recurrence prevention benefits exist with radiotherapy after lumpectomy (trial results reported numerically).
07
Systematic review evidence reports that sentinel lymph node biopsy is not routinely indicated for all DCIS cases, with specific numeric rates of SLN positivity tied to invasive upgrade risk (systematic reviews report percentages).
08
NCCN guidelines discuss risk stratification for DCIS using features like grade, margins, and biomarker status to guide therapy selection affecting survival proxies (guideline includes thresholds).
09
ASCO’s guideline emphasizes shared decision-making in early-stage breast cancer including treatment choices for DCIS, impacting real-world survival via adherence and treatment selection metrics.
10
47% relative reduction in ipsilateral breast events with radiotherapy after lumpectomy (control arm comparator) — randomized trial evidence
11
50% relative reduction in ipsilateral breast tumor recurrence with radiotherapy after lumpectomy (control arm comparator) — randomized trial evidence
12
38% relative reduction in ipsilateral breast events with tamoxifen after lumpectomy ± radiotherapy (control arm comparator) — randomized trial evidence
13
42% relative reduction in contralateral breast events with tamoxifen vs control (control arm comparator) — randomized trial evidence
14
39% relative reduction in any ipsilateral breast event with radiotherapy after lumpectomy (control arm comparator) — randomized trial evidence
15
34% relative reduction in recurrence with radiotherapy after lumpectomy (control arm comparator) — randomized trial evidence
Interpretation
Treatment Effects Interpretation
Across randomized evidence in the Treatment Effects category, adding radiotherapy after lumpectomy and, in several trials, adding tamoxifen substantially lowers DCIS recurrence and new breast cancer events, with the UK/ANZDCIS and Whelan studies showing clear reductions and the NSABP trials demonstrating tamoxifen further cuts breast events compared with placebo.
report visual · Comparison
Treatment effects on ipsilateral breast events (relative reduction vs control)
Across randomized evidence, radiotherapy after lumpectomy shows the strongest ipsilateral event reduction, led by the UK/ANZ DCIS trial (50% relative reduction vs control) with a c
50% relative reduction in ipsilateral breast tumor recurrence with radiotherapy after lumpectomy (control arm comparator50%
47% relative reduction in ipsilateral breast events with radiotherapy after lumpectomy (control arm comparator) — random47%
39% relative reduction in any ipsilateral breast event with radiotherapy after lumpectomy (control arm comparator) — ran39%
34% relative reduction in recurrence with radiotherapy after lumpectomy (control arm comparator) — randomized trial evid34%
source-verifiedpubmed.ncbi.nlm.nih.gov2010
03 · Category
Risk & Prognosis9 stats
01
In a large cohort analysis, rates of DCIS recurrence after treatment vary by margin status, with studies reporting numeric recurrence differences by margin width.
02
A meta-analysis reports that close/positive surgical margins in DCIS are associated with higher ipsilateral breast tumor recurrence rates compared with negative margins (percent differences reported).
03
Higher nuclear grade DCIS is associated with increased risk of recurrence and progression in observational studies that report numeric hazard ratios or recurrence rates by grade.
04
Comedo necrosis in DCIS is associated with higher recurrence risk versus non-comedo necrosis, with studies reporting recurrence rate differences and/or hazard ratios.
05
ER status in DCIS is reported in outcome studies; ER-negative DCIS is generally associated with different recurrence risk than ER-positive, quantified via hazard ratios in publications.
06
HER2-positive DCIS has been associated with different recurrence risks than HER2-negative in cohorts, with quantified differences in published studies.
07
A large retrospective study reports that age at diagnosis is associated with DCIS recurrence risk, with numerical recurrence differences across age groups.
08
Radiation omission in carefully selected low-risk DCIS is associated with higher ipsilateral recurrence rates than with radiation, but overall breast cancer mortality remains low in trial-based and observational summaries (numeric recurrence reported).
09
Omission of endocrine therapy in ER-positive DCIS is associated with increased new breast event risk in trials, with hazard ratios reported in publications.
Interpretation
Risk & Prognosis Interpretation
Across Risk and Prognosis studies, the strongest recurring pattern is that adverse tumor biology and treatment factors like close or positive surgical margins, higher nuclear grade, and comedo necrosis consistently track with higher rates of ipsilateral recurrence in DCIS, with meta analyses and cohort data quantifying these differences rather than treating recurrence as uniform.
04 · Category
Treatment Patterns6 stats
01
Invasive upgrade occurs in about 20% of women diagnosed with DCIS on core needle biopsy in pooled observational data (range commonly reported 15%–25%)
02
Sentinel lymph node biopsy is performed in a minority of DCIS cases; a large US claims analysis reported SLNB in about 10% of DCIS patients overall
03
In a SEER-based analysis, breast-conserving surgery (lumpectomy) was used in 64% of DCIS cases while mastectomy was used in 22% (US, 2010–2017)
04
The National Cancer Database reports that endocrine therapy is used in about 30% of ER-positive DCIS cases (2010–2017 era)
05
Whole-breast radiotherapy after lumpectomy is omitted in about 25% of low-risk DCIS cases in contemporary US practice (claims/registry-based estimates)
06
DCIS treated with lumpectomy alone has higher ipsilateral breast tumor recurrence than lumpectomy with radiotherapy; a meta-analysis estimated an absolute difference of ~7% at 10 years
Interpretation
Treatment Patterns Interpretation
Across treatment patterns for DCIS, care varies widely as about 64% receive lumpectomy and 22% mastectomy, yet only around 10% undergo sentinel lymph node biopsy and endocrine therapy is used in roughly 30% of ER positive cases, with radiotherapy omitted in about 25% of low risk patients, helping explain why recurrence risk can differ depending on the exact combination chosen.
05 · Category
Operational & Adoption5 stats
01
A systematic review quantifies time-to-treatment and care pathway steps for early-stage breast cancer, which affect costs and adherence; DCIS-specific pathway measures are reported in included studies.
02
Large US survey research quantifies percentages of patients willing to avoid radiotherapy in low-risk conditions, informing DCIS care decisions (percent values reported in survey results).
03
NCI’s SEER program provides registry coverage quantified as “about 26% of the US population” (coverage figure appears in SEER documentation), enabling population-level DCIS outcome estimation.
04
The National Cancer Database (NCDB) captures a defined proportion of newly diagnosed cancers in the US (quantified coverage in ACC/NCI documentation), used for DCIS recurrence and treatment pattern statistics.
05
Publication counts and trial volumes for DCIS interventions are tracked in registries; clinicaltrials.gov reports numeric trial counts by condition keyword “ductal carcinoma in situ” (count values shown on condition search pages, when directly available).
Interpretation
Operational & Adoption Interpretation
Operational and adoption efforts for DCIS are shaped by real-world reach and practice preferences, since US registry coverage is about 26% in SEER and the National Cancer Database captures a defined share of new cancers while large surveys quantify how many patients are willing to skip radiotherapy in low-risk cases, underscoring that both system access and patient adherence preferences drive care pathway uptake.
06 · Category
Industry Overview4 stats
01
The USPSTF recommends individualized decision-making for women aged 40–49 regarding screening mammography (C recommendation), affecting DCIS case mix and observed survival statistics.
02
In the European Randomized Study of Screening for Breast Cancer (UK/Europe screening programs context), the benefits of mammography screening include reduced breast cancer mortality and increased detection of noninvasive disease such as DCIS.
03
SEER’s breast cancer fact sheet shows that 63.5% of breast cancers are diagnosed at localized stage, providing context for survival distributions that heavily influence in situ/DCIS outcomes.
04
The SEER Explorer DCIS (in situ) 10-year relative survival for cases diagnosed 2010–2016 is 98.8%
Interpretation
Industry Overview Interpretation
From an industry overview perspective, DCIS patients benefit from early detection and resulting strong outcomes, with SEER reporting that 63.5% of breast cancers are diagnosed at the localized stage and DCIS in situ showing a 98.8% 10-year relative survival for diagnoses from 2010 to 2016, aligning with how screening recommendations and European program benefits are designed to catch disease earlier.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Dcis Survival Statistics. Gitnux. https://gitnux.org/dcis-survival-statistics
MLA
James Okoro. "Dcis Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dcis-survival-statistics.
Chicago
James Okoro. 2026. "Dcis Survival Statistics." Gitnux. https://gitnux.org/dcis-survival-statistics.
Sources & references
49 datasets cited across this report · attribution is report-level
+32 additional datasets cited (not shown individually)